Your session is about to expire
← Back to Search
Avelumab + Lenvatinib for Brain Cancer
Study Summary
This trial will test if a combination of two drugs is safe and effective in treating primary central nervous system tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 19 Patients • NCT03006848Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My tumor is large or causing significant pressure inside my brain.My seizures are under control and do not affect my daily activities.I have not had major surgery or brain treatment in the last 28 days.I have a high-grade brain tumor and have had at least one treatment, or I have a specific type of brain tumor (diffuse midline glioma) and may have had up to one treatment or just radiotherapy.I can do most activities by myself, regardless of my age.I have a low-grade brain tumor, such as a pilocytic astrocytoma.I have not had a brain or spinal cord bleed in the last 28 days.My neurological condition has worsened in the past week.
- Group 1: Avelumab + Lenvatinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any precedents of utilizing Avelumab in clinical experiments?
"Currently, there are 258 clinical trials exploring Avelumab with 42 of these studies being in the advanced Phase 3 stage. While numerous experiments for this medication take place in Nanning, Guangxi, a total of 8664 sites across the world are providing access to such research."
What is the aggregate number of people engaged in this research project?
"Affirmative. Clinicaltrials.gov provides evidence that this medical experiment, which was initially advertised on December 3rd 2021, is now actively sourcing patients. 50 candidates need to be sourced from 4 distinct research centres."
For what ailments is Avelumab typically prescribed?
"Avelumab is frequently utilized in treating malignant neoplasms, as well as more specialized conditions such arcc, directives of progression, and radioactive iodine-refractory thyroid cancer."
Is enrollment for this medical experiment still open?
"Affirmative. According to the information posted on clinicaltrials.gov, this trial is seeking participants and has been since December 3rd 2021; with its last update occurring November 4th 2022. This experiment requires 50 individuals from 4 distinct medical centers to complete it."
To whom is this research opportunity available?
"This clinical trial requires participants to have tumors within the central nervous system and be aged between two and eighteen. The study is currently seeking a total of fifty patients."
Is this research groundbreaking in its approach?
"Currently, the world-wide count of active studies using Avelumab stands at 258 across 1775 cities and 60 countries. The initial study was conducted in 2014 by EMD Serono Research & Development Institute, Inc., with 204 participants and concluded Phase 2 drug approval. Subsequent research has been carried out 102 times since then."
What safety checks have been implemented to ensure the use of Avelumab is not hazardous?
"Considering the limited information at this stage of a Phase 1 trial, Avelumab was assigned an assessment score of 1."
Are individuals aged 35 and above eligible to participate in this trial?
"This research project is seeking participants aged 2 to 18. The clinical trials registry reveals that there are 87 studies for minors and 303 intended for senior citizens."
How extensive is the geographic coverage of this trial's implementation?
"The research team is seeking volunteers for this clinical trial from 4 different locations, including Washington University in Saint Louis, CHU Sainte-Justine in Montréal, and The Hospital for Sick Children in Toronto. Additionally, there are an additional four sites participating throughout the US and Canada."
Share this study with friends
Copy Link
Messenger